Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

IQVIA Holdings, Inc. Common Stock (NY:IQV)

206.50 +2.73 (+1.34%)
Streaming Delayed Price Updated: 3:27 PM EDT, Oct 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about IQVIA Holdings, Inc. Common Stock

< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
World Wrestling Entertainment To Rally Around 12%? Here Are 10 Other Analyst Forecasts For Tuesday
Goldman Sachs boosted the price target for The Wendy's Company (NASDAQ: WEN) from $22 to $25. Goldman Sachs analyst Jared Garber maintained a Neutral rating on the stock. Wendy's shares fell 1.4% to... 
Via Benzinga
Analyst Ratings for IQVIA Hldgs
 
Via Benzinga
2 Unstoppable Growth Stocks to Buy in 2023 and Beyond
These healthcare companies' revenue and earnings have grown, and they expect more growth. 
Via The Motley Fool
Expert Ratings for IQVIA Hldgs
 
Via Benzinga
Veracyte Stock Showing Market Leadership; Earns 93 RS Rating
Veracyte shows rising price performance, earning an upgrade to its IBD Relative Strength Rating. 
Via Investor's Business Daily
Where IQVIA Hldgs Stands With Analysts
 
Via Benzinga
Target To Rally 29%? Plus This Analyst Predicts $245 For IQVIA Holdings
Piper Sandler boosted the price target on Target Corporation (NYSE: TGT) from $190 to $200. Target shares fell 13.1% to close at $155.47 on Wednesday. 
Via Benzinga
Analyst Ratings for IQVIA Hldgs
 
Via Benzinga
8 Analysts Have This to Say About IQVIA Hldgs
IQVIA Hldgs (NYSE:IQV) has observed the following analyst ratings within the last quarter: 
Via Benzinga
7 Analysts Have This to Say About IQVIA Hldgs
Analysts have provided the following ratings for IQVIA Hldgs (NYSE:IQV) within the last quarter: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 6, 2022
 
Via Benzinga
IQVIA and Clalit Health Services partner to advance research by launching the first Prime Site in Israel
From IQVIA
Via Business Wire
Expert Ratings for IQVIA Hldgs
Analysts have provided the following ratings for IQVIA Hldgs (NYSE:IQV) within the last quarter: 
Via Benzinga
6 Analysts Have This to Say About IQVIA Hldgs
Analysts have provided the following ratings for IQVIA Hldgs (NYSE:IQV) within the last quarter: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 17, 2022
Upgrades 
Via Benzinga
General Electric To Rally Around 14%? Here Are 5 Other Price Target Changes For Thursday
  Morgan Stanley raised General Electric Company (NYSE: GE) price target from $85 to $88. Morgan Stanley analyst Joshua Pokrzywinski maintained the stock with an Overweight rating. GE shares rose 2.2%... 
Via Benzinga
What 5 Analyst Ratings Have To Say About IQVIA Hldgs
Within the last quarter, IQVIA Hldgs (NYSE:IQV) has observed the following analyst ratings: 
Via Benzinga
IQVIA: Q3 Earnings Insights
IQVIA Hldgs (NYSE:IQV) reported its Q3 earnings results on Wednesday, October 26, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings IQVIA Hldgs beat estimated... 
Via Benzinga
IQVIA Reports Third-Quarter 2022 Results
From IQVIA Holdings Inc.
Via Business Wire
Medpace Earnings Are 'Almost Unbelievable'; MEDP Stock Flies
Medpace earnings soared in Q3 as weakness in contract awards turned to strength, sending MEDP stock surging. 
Via Investor's Business Daily
Biosimilars Are Revolutionizing Healthcare: Is This Industry Leader a Buy?
Biosimilars are bringing down prescription drug costs without sacrificing quality. 
Via The Motley Fool
IQVIA CFO Ron Bruehlman to Speak at Credit Suisse Annual Healthcare Conference on November 8, 2022
From IQVIA Holdings Inc.
Via Business Wire
Q² Solutions Launches Innovative Self-Collection Safety Lab Panel in Collaboration With Tasso
From IQVIA
Via Business Wire
Tesla To $370? Plus HC Wainwright Slashes PT On This Stock By 67%
HC Wainwright & Co. cut KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) price target from $48 to $16. KalVista Pharmaceuticals shares fell 1.8% to $5.06 in pre-market trading. 
Via Benzinga
IQVIA to Announce Third-Quarter 2022 Results on October 26, 2022
From IQVIA Holdings Inc.
Via Business Wire
IQVIA Decentralized Clinical Trial Program Achieves Independent GDPR Validation
From IQVIA
Via Business Wire
New IQVIA Study Demonstrates Cost and Time Savings of Decentralized Trials
From IQVIA
Via Business Wire
IQVIA CEO Ari Bousbib to Speak at Baird Global Healthcare Conference on September 14, 2022
From IQVIA
Via Business Wire
IQVIA CFO Ron Bruehlman to Speak at Morgan Stanley Annual Global Healthcare Conference on September 13, 2022
From IQVIA Holdings Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For August 25, 2022
Upgrades 
Via Benzinga
< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.